InsidersTradesSigma
Explore the complete record of transactions filed by Eckelman Brendan P., Directeur scientifique. Officer active across 1 companies, notably Inhibrx, Inc.. Cumulatively, 1 disclosures have been logged. Total volume traded: €9k. The latest transaction was filed on 5 April 2022 — Cession. Regulator: SEC (Form 4). The full history is accessible without signup.
1 of 1 declaration
Brendan P. Eckelman is the Chief Scientific Officer at Inhibrx, Inc. He is responsible for leading scientific initiatives and research within the company. His expertise is crucial for the development of new products and innovation.